Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep;5(4):858-61.
doi: 10.5812/numonthly.11523. Epub 2013 Jul 29.

Testosterone replacement therapy: should it be performed in erectile dysfunction?

Orcun Celik  1 , Selcuk Yücel  2
Affiliations
Review

Testosterone replacement therapy: should it be performed in erectile dysfunction?

Orcun Celik et al. Nephrourol Mon. 2013 Sep.

Abstract

The classical etiology of erectile dysfunction (ED) comprises aging and vascular, neurogenic, psychological and hormonal components. Recent studies have shown that ED can be the forerunner of serious cardiovascular disturbances. It has also been reported that peripheral neuropathy and microvascular injuries caused by pathophysiological changes in patients with diabetes and obesity lead to ED in a significant number of such cases. These patients develop clinically significant ED and comprise a significant portion of the patient group which do not respond to PDE-5 inhibitors. Testosterone has been shown to increase the expression of PDE-5. This function of testosterone supports its effect on the regulation of erection and increasing the sexual libido. In view of the complexity of ED, as well as the effect of testosterone on erection, it is concluded that PDE-5 inhibitors in combination with testosterone replacement would be a better therapy alternative in the management of erectile dysfunction in hypogonadal patients.

Keywords: Erectile Dysfunction; Testosterone; Therapeutics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84(1):50–6. - PubMed
    1. Bivalacqua TJ, Usta MF, Champion HC, Adams D, Namara DB, Abdel-Mageed AB, et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol. 2003;169(5):1911–7. doi: 10.1097/01.ju.0000051881.14239.4a. - DOI - PubMed
    1. Roumeguere T. Rationale for androgens and erectile dysfunction in 2006. Eur Urol. 2006;50(5):898–900. doi: 10.1016/j.eururo.2006.06.048. - DOI - PubMed
    1. Buvat J, Bou Jaoude G. Significance of hypogonadism in erectile dysfunction. World J Urol. 2006;24(6):657–67. doi: 10.1007/s00345-006-0131-x. - DOI - PubMed
    1. Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM, Tan HM, et al. Endocrine aspects of sexual dysfunction in men. J Sex M. 2004;1(1):69–81. - PubMed

LinkOut - more resources